News

A look back at some of the biggest stories in 2023, from our US partners at Ophthalmology Times

From FDA approvals to innovations in lens tech, 2023 was a big year in eye care

A review of our most important content from throughout the year

Real-world data from using faricimab to treat neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME)

The technology provides effective, efficient evaluations when paired with the right patients

In 2024, the waiting game will pay off for glaucoma specialists who are eager to develop fluency and implement new devices into their practices

Analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with primary open-angle glaucoma

The case for treating keratoconus without waiting for disease progression

Why “acceleration” is the industry keyword for 2024

The study results will help to identify dosing levels for future clinical trials

Working smarter, not harder, to benefit patients

Orbis advances cataract surgery training in low-resource areas with technology

Experts from around the globe converged in San Francisco, California

Austrian investigators recommend an interdisciplinary, rheumatologic–ophthalmologic approach to disease management

Restoration and regeneration represent a new paradigm

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

In recognition of global Geographic Atrophy Week, Prevent Blindness is providing free educational resources on GA for patients, care partners and healthcare professionals

At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research

Data show transfection in both eyes despite unilateral injection

In early November, the EU MDR issued a CE mark certification for RetInSight’s AI-based geographic atrophy monitor

The carbomer-containing eye gels carry risk of microbial contamination, the regulatory agency warned

Moving toward eliminating drug and chemical safety testing in animals

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

Patients who received digital education demonstrated a better understanding of their disease and its management

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

Dr Marco Zarbin emphasises the importance of defining “active disease”

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint